Key clinical point: Patients with rheumatoid arthritis (RA) who are not obese, those who have high initial disease activity, and those with long disease duration are more responsive to tumor necrosis factor (TNF) inhibitors.
Major finding: The risk for European League Against Rheumatism nonresponse was significantly higher in patients with obesity vs. those with a body mass index of <30 kg/m 2 (odds ratio 0.52 vs. 0.36; P = .01). Among patients treated with TNF inhibitors, the final Disease Activity Score on 28 joints-C-reactive protein (DAS28-CRP) decreased by 0.02 each year of disease duration ( P < .001), with a reduction of 0.21 in patients with a baseline DAS28-CRP of >5.1 ( P = .05).
Study details: This was a pooled analysis of individual patient data of 11,617 patients with RA from 29 randomized controlled trials.
Disclosures: This work was partly supported by the French Higher Education and Research Ministry. P Goupille and D Mulleman declared serving as a consultant or speaker, participating in international congresses or clinical trials, and receiving grants from various sources.
Source: Law-Wan J et al. RMD Open. 2021;7(3):e001882 (Nov 17). Doi: 10.1136/rmdopen-2021-001882.